CD209 and myeloid sarcoma: This subset was also identified (cluster 155313) using CITRUS as enriched in MS patients compared to HC, and corresponded to a subset of classical monocytes with an increased expression of pro-inflammatory (CD86, CD64, CD32) and regulatory (CD206, CD209, PD-L1) markers (Figures 3B, C).